Superluminal Medicines secured an oversubscribed $60 million Series B round to drive its pipeline forward and support a first clinical study for endocrine and cardiometabolic targets. The company’s focus is on next-generation small-molecule GPCR therapeutics and it says it integrates AI/ML, protein dynamics, and structural biology for hard GPCR drug-discovery work. The funding milestone is explicitly tied to execution toward early human testing, indicating a shift from platform maturation to clinical validation for at least one program. For investors, the round highlights continued appetite for modality- and platform-driven drug discovery in cardiometabolic disease, particularly where GPCR biology is tractable but chemically challenging. For the broader sector, it adds to the signal that capital markets are increasingly rewarding companies with credible translational plans and data packages aligned to early clinical endpoints.